Welcome to our dedicated page for Polyrizon Ltd. SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. Chief Financial Officer BenYosef Nir has filed an initial statement of beneficial ownership, detailing his current equity position in the company. He holds an option to purchase 2 ordinary shares at an exercise price of 1699.3000 per share, expiring on December 26, 2026, alongside direct holdings of ordinary shares.
Footnotes explain that portions of these ordinary shares are restricted and vest over time. One grant vests in 8 equal monthly installments on a quarterly basis beginning on March 30, 2026, while another includes 104 already vested shares and 625 restricted shares vesting in 6 equal quarterly installments beginning on March 31, 2026, all subject to his continued service and structured to qualify for Israeli Section 102 tax benefits through a trustee arrangement.
Polyrizon Ltd. reports that it has signed an agreement with a leading global preclinical contract research organization to support its clinical development program for intranasal hydrogel-based medical devices. The CRO will run a package of biocompatibility studies under ISO 10993 standards and GLP requirements.
The studies are expected to begin in the second quarter of 2026 and are described as a key milestone on Polyrizon’s regulatory path toward starting clinical trials planned for later this year. The program will test cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity and pyrogenicity to help demonstrate product safety before human studies.
Polyrizon Ltd. filing reports that Eli Zamir holds beneficial ownership of the issuer's Ordinary Shares at a level of 5% or less as of 12/31/2025. The filing lists the issuer's principal office in Raanana, Israel, and is signed on 03/16/2026.
Polyrizon Ltd. reported that it has successfully produced a Good Manufacturing Practice (GMP) batch of clinical trial material for its lead intranasal product candidate, working with Eurofins CDMO AmatsiAquitaine S.A.S. This batch will supply a planned clinical study in the United States later this year.
The GMP lot follows two earlier development batches that showed consistent manufacturing performance and product stability, supporting a robust, reproducible process. Polyrizon views this manufacturing milestone as an important step in advancing its clinical development strategy and its intranasal technology platform aimed at protecting against airborne allergens and viruses.
Polyrizon Ltd. received an amended Schedule 13G/A from L.I.A. Pure Capital Ltd. reporting beneficial ownership of 5 percent or less of the company's ordinary shares.
The filing references the cover pages for details on voting and dispositive powers and identifies the reporting person and its Israeli address and citizenship.
Polyrizon Ltd., a pre-clinical-stage biotech company focused on intranasal technologies, reported results from a comparative study of its naloxone nasal formulation against a commercial reference product. Using a validated silicone nasal cast model at the University of Parma’s Biopharmanet-TEC research center, the study evaluated where in the nose each product was deposited.
Polyrizon’s formulation showed significantly higher deposition in the highly vascularized upper/anterior nasal region, which is important for rapid systemic drug absorption. The company views these data as supporting its Trap & Target™ platform’s ability to control regional nasal deposition and is continuing to advance its naloxone program within a broader intranasal platform strategy.
Polyrizon Ltd. reported that it has signed a development agreement with Clearmind Medicine Inc. to create a proprietary intranasal formulation of MEAI, Clearmind’s non-hallucinogenic neuroplastogen drug candidate. The formulation is intended for treating addiction-related and other central nervous system conditions.
The collaboration uses Polyrizon’s intranasal delivery technology to advance an intranasal MEAI product that is expected to support Clearmind’s future clinical development programs. Polyrizon positions this deal as reinforcing its role as a partner for companies seeking specialized intranasal drug-delivery capabilities.
Polyrizon Ltd. has signed a non-binding Memorandum of Understanding to acquire a 51% stake in Arrow Aviation Ltd., a global private aviation company. Polyrizon plans to invest NIS 18,000,000 (approximately $5.8 million) in cash for this majority position on a fully diluted basis.
Arrow Aviation generates annual unaudited revenues of about $19 million and adjusted EBITDA of about $3 million, operating a fleet of executive jets and providing VIP, medical, government, and cargo aviation services. Ancillary arrangements include transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation in exchange for a Polyrizon convertible note, and converting Arrow’s shareholder debts into additional Polyrizon convertible notes so Arrow would have no institutional debt after closing.
The MOU also provides mutual call and put options on the remaining 49% of Arrow Aviation shares, exercisable after two years based on agreed valuation multiples, potentially leading to 100% ownership. A definitive agreement is expected within 30 days, subject to due diligence and customary closing conditions.
Polyrizon Ltd. filed a Form 6-K reporting the start of a key FDA-aligned usability (human factors) study for its lead product candidate, NASARIX™, an intranasal allergy blocker intended for broad consumer use. The study focuses on how users interact with the product, including labeling, instructions for use, and overall handling, to support future U.S. Food and Drug Administration review.
Successful completion is expected to provide important regulatory evidence for NASARIX readiness for clinical evaluation and represents a milestone toward Polyrizon’s planned clinical trials, which are expected to commence in Q3 2026. Polyrizon develops hydrogel-based nasal spray technologies designed to act as a protective barrier against viruses and allergens and to enable intranasal delivery of active drugs.
Polyrizon Ltd. reported that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the name NASARIX™. PL-14 is a pre-clinical intranasal product based on Polyrizon’s proprietary Capture and Contain™ hydrogel technology, designed to form a physical barrier in the nasal cavity against allergens and viruses.
The company conducted trademark screening and linguistic evaluations in the U.S. and European markets to support the new brand. Management describes NASARIX™ as an important step toward future commercialization and commercial readiness, with the product expected to be introduced in alignment with Polyrizon’s ongoing clinical progress and regulatory pathway.